247 related articles for article (PubMed ID: 32974848)
1. Metabolic changes in breast cancer on dual-time-point
Kim HO; Kim BS; Kang SY; Bang JI; An J; Kim JH; Yoon HJ
Ann Nucl Med; 2020 Dec; 34(12):942-951. PubMed ID: 32974848
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
3. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
4. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
5. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
7. Limited diagnostic value of Dual-Time-Point (18)F-FDG PET/CT imaging for classifying solitary pulmonary nodules in granuloma-endemic regions both at visual and quantitative analyses.
Chen S; Li X; Chen M; Yin Y; Li N; Li Y
Eur J Radiol; 2016 Oct; 85(10):1744-1749. PubMed ID: 27666611
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric
Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Activity of Normal Glandular Tissue on
An YS; Jung Y; Kim JY; Han S; Kang DK; Park SY; Kim TH
J Breast Cancer; 2017 Dec; 20(4):386-392. PubMed ID: 29285044
[TBL] [Abstract][Full Text] [Related]
11. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
12. Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer.
Garcia-Vicente AM; Molina D; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Bueno G; Tello-Galán MJ; Soriano-Castrejón Á
Ann Nucl Med; 2017 Dec; 31(10):726-735. PubMed ID: 28887761
[TBL] [Abstract][Full Text] [Related]
13. Assessing
Sarikaya I; Sarikaya A
J Nucl Med Technol; 2019 Jun; 47(2):149-153. PubMed ID: 30413593
[No Abstract] [Full Text] [Related]
14. A multiparametric [
Leithner D; Horvat JV; Bernard-Davila B; Helbich TH; Ochoa-Albiztegui RE; Martinez DF; Zhang M; Thakur SB; Wengert GJ; Staudenherz A; Jochelson MS; Morris EA; Baltzer PAT; Clauser P; Kapetas P; Pinker K
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1878-1888. PubMed ID: 31197455
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.
Rogasch JM; Steffen IG; Riedel S; Apostolova I; Wertzel H; Achenbach HJ; Steinkrüger FL; Kalinski T; Schultz M; Schreiber J; Amthauer H; Furth C
Eur Radiol; 2016 Aug; 26(8):2808-18. PubMed ID: 26560731
[TBL] [Abstract][Full Text] [Related]
17. Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.
Sasada S; Masumoto N; Suzuki E; Sueoka S; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):831-837. PubMed ID: 30648199
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
20. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
